
Jeff Hatfield assembles a syndicate with some A-list public investors in the mix as Vividion adds $135M raise
Back when Vividion put together its $82 million B round more than a year ago, I speculated that the startup was probably gearing up for an IPO. That still hasn’t happened, but they may be a lot closer after today.
The ARCH- and Versant-backed company just nailed down a $135 million raise from a dream team of crossover investors, with Logos Capital and Boxer Capital leading as SoftBank jumps in with Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital and Driehaus Capital Management. Existing investors ARCH Venture Partners, BVF Partners L.P., Casdin Capital, Mubadala Capital, Nextech Invest and Versant Ventures all came back to chip in.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.